TuHURA Biosciences files amended 8-K with pro forma Kineta merger financials

• TuHURA filed an amended Form 8-K/A updating unaudited pro forma condensed combined financial information tied to its June 30, 2025 acquisition of Kineta under purchase accounting.
• Pro forma results for fiscal 2025 showed combined net loss attributable to common stockholders of $34.57 million, or $0.66 per share, on weighted-average basic and diluted shares of 52,737,089.
• The filing also presented estimated purchase consideration of $16.56 million, including $7.64 million of cash paid through prior exclusivity payments, loans, and advances, plus $8.92 million of share consideration.
• Preliminary allocation included $11.28 million of in-process R&D intangible assets and $10.74 million of goodwill.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-197609), on April 30, 2026, and is solely responsible for the information contained therein.